The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | ERAKI WG

ERAKI WG


6 / 6 results found

{%SMALL_TITLE%}
{%SUMMARY_INFO%}

{%BOTTOM_TEXT%}

{%SMALL_TITLE%}

{%EXCERPT%}

{%BOTTOM_TEXT%}

Speaker
Yvelynne Kelly, Ireland

Panellists
Carlo Alfieri, Italy
Turgay Saritas, Germany

Moderator
Nick Selby, United Kingdom